跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
林 怡慈
主治醫師
,
臺北市立萬芳醫院
電子郵件
109221
w.tmu.edu
tw
h-index
60
引文
5
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2009
2025
每年研究成果
概覽
指紋
網路
研究成果
(8)
類似的個人檔案
(6)
指紋
查看啟用 Yi-Tsz Lin 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Acrylic Acid
64%
Acrylic Acid Derivative
85%
Adverse Event
14%
Antipruritic
9%
Aprepitant
19%
Cancer Types
14%
Cell Signaling Pathway
9%
Clinician
9%
Contact Allergen
21%
Cosmetic
21%
Cosmetics
85%
Dermatological Disease
19%
Diseases
9%
Hand Eczema
21%
Immune Checkpoint Inhibitor
85%
Immune-Related Adverse Events
85%
Immunotherapy
57%
Log Rank Test
14%
Maculopapular Rash
14%
Malignant Neoplasm
85%
Meta-Analysis
85%
Molecularly Targeted Therapy
14%
Monotherapy
14%
Nail Dystrophy
21%
Neurokinin 1 Receptor
19%
Neurokinin 1 Receptor Antagonist
85%
Oncology
14%
Overall Survival
14%
Patch Test
21%
Patient Referral
14%
Pembrolizumab
14%
Placebo
28%
Pruritus
100%
Pulpitis
21%
Randomized Controlled Trial
47%
Retrospective Cohort Study
14%
Sensitization
21%
Serlopitant
19%
Skin Allergy
85%
Subgroup Analysis
9%
Substance P
9%
Survival Rate
14%
Survival Time
14%
Systematic Review
85%
Therapy Effect
9%
Treatment Duration
9%
Neuroscience
Antipruritic
8%
Aprepitant
17%
Immunotherapy
85%
Lambrolizumab
21%
Meta-Analysis
85%
Neurokinin 1 Receptor
85%
Placebo
25%
Randomized Controlled Trial
42%
Receptor Antagonist
85%
Substance P
8%
Systematic Review
85%
Pharmacology, Toxicology and Pharmaceutical Science
Antipruritic Agent
9%
Aprepitant
19%
Diseases
9%
Neurokinin 1 Receptor
19%
Neurokinin 1 Receptor Antagonist
85%
Placebo
28%
Pruritus
85%
Randomized Controlled Trial
47%
Serlopitant
19%
Substance P
9%
Therapeutic Effect
9%
